TECH offers you a unique academic experience that will allow you to be up to date in Advanced Neuropharmacology, without neglecting your personal responsibilities”

Patients suffering from pathologies with a high incidence such as Epilepsy, frequent Migraine or the autoimmune disease Myasthenia Gravis have found in pharmacological advances important advances in their treatments and diagnoses. In this sense, studies on neurological diseases have made it possible to improve the quality of life of the people who suffer from them and to incorporate the most relevant advances into clinical practice.

In this context, pharmacists, especially those in hospital environments, must be aware of the most notorious progress, the techniques used for patient management and the pharmacology used. Thus, this 6-month Postgraduate diploma in Advanced Neuropharmacology was born.

It is an intensive program that provides students with advanced information on the pathophysiology and drugs used for the main diseases affecting the Central Nervous System, as well as those used for seizures and headaches. Likewise, special emphasis will be placed on treatments for surgical and polytraumatized patients.

To achieve this update, the graduates have at their disposal video summaries of each topic, in in focus videos, case studies and specialized readings to further extend the information provided in this syllabus.

Undoubtedly, a unique opportunity to get a quality update through a convenient and flexible academic proposal. The pharmacist only needs a mobile device, tablet or computer with Internet connection to view the content hosted on the virtual platform at any time of the day. An ideal option for those seeking to reconcile their daily activities with a cutting-edge program.

Thanks to the Relearning method you will be able to reduce the long hours of study and consolidate the concepts addressed in less time”

This Postgraduate diploma in Advanced Neuropharmacology contains the most complete and up-to-date scientific program on the market. The most important features include:

• The development of practical cases presented by experts in Pharmacy, Hospital Management, among others
• Graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Practical exercises where self-assessment can be used to improve learning
• Its special emphasis on innovative methodologies
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

This academic proposal will keep you up to date with the latest scientific evidence on pharmacology in patients with cerebral edema”

The program’s teaching staff includes professionals from sector who contribute their work experience to this educational program, as well as renowned specialists from leading societies and prestigious universities.

Its multimedia content, developed with the latest educational technology, will provide the professionals with situated and contextual learning, i.e., a simulated environment that will provide an immersive education programmed to learn in real situations.

The design of this program focuses on Problem-Based Learning, by means of which the professionals must try to solve the different professional practice situations that are presented throughout the academic course. For this purpose, the students will be assisted by an innovative interactive video system created by renowned experts.

TECH adapts to you and for this reason has created an online program without classes with restricted schedules. Get updated at your own pace"

With this university qualification you will be up to date with emerging therapies for Migraine"

The effectiveness of the Relearning Method, has led TECH to use it in all its qualifications. With this system, the pharmacists will achieve a complete update, without the need to invest long hours of study and memorization. In this way, the reiteration of the key concepts will lead you to increase your knowledge of Advanced Neuropharmacology throughout the 3 modules that make up this Postgraduate diploma.

This academic course will allow you to be updated on the pathophysiological mechanisms of stroke patients, as well as the pharmacology related to its management”

Module 1. Pharmacology of Epilepsy, Migraine and Myasthenia Gravis

1.1. Adult Patient Seizures

1.1.1. Classification of Seizures
1.1.2. Differential diagnosis and clinical evaluation
1.1.3. Neuroimaging Studies in Diagnosis
1.1.4. Pharmacological treatment of seizures in the adult patient

1.2. Seizures in the pediatric patient

1.2.1. Classification of seizures in the pediatric patient
1.2.2. Differential diagnosis and clinical evaluation of seizures in the pediatric patient
1.2.3. Neuroimaging studies in the diagnosis of seizures in the pediatric patient
1.2.4. Febrile seizures in childhood

1.3. Status Epilepticus (SE) in the adult patient

1.3.1. Diagnosis and clinical evaluation of Status Epilepticus
1.3.2. Neurophysiological evaluation and neuroimaging in Status Epilepticus
1.3.3. Causes and triggers of Status Epilepticus in adults
1.3.4. Emergency management and treatment of Status Epilepticus in the adult patient

1.4. SE in the pediatric patient

1.4.1. Diagnosis and clinical evaluation of Status Epilepticus in the pediatric patient
1.4.2. Neurophysiological assessment and neuroimaging in pediatric Status Epilepticus
1.4.3. Causes and triggers of Status Epilepticus in children
1.4.4. Emergency management and treatment of Status Epilepticus in the pediatric patient

1.5. Management of Myasthenia Gravis (MG)

1.5.1. Classification of Myasthenia Gravis
1.5.2. Pharmacological Treatment of Myasthenia Gravis
1.5.3. Management of myasthenic crisis and acute exacerbations of myasthenia gravis
1.5.4. Immunomodulatory and biological therapies in myasthenia gravis

1.6. Headache and Migraine in the adult patient

1.6.1. Classification of primary and secondary headaches
1.6.2. Clinical evaluation and differential diagnosis of headache and Migraine in the adult patient
1.6.3. Initial therapeutic approach and management of episodic migraine
1.6.4. Migraine prophylaxis and prevention of chronic migraine headaches

1.7. Headache and Migraine in the pediatric patient

1.7.1. Classification of primary and secondary headaches in children
1.7.2. Clinical evaluation and differential diagnosis of headache and Migraine in the pediatric patient
1.7.3. Differences in the presentation and manifestation of Migraine in children and adults
1.7.4. Acute pharmacological treatment of migraine attacks in children

1.8. Hypertensive Emergencies

1.8.1. Classification and categories of hypertensive emergency
1.8.2. Clinical Evaluation and Diagnosis of Hypertensive Emergencies
1.8.3. Complementary tests and laboratory studies for the evaluation of hypertensive emergency
1.8.4. Differentiation between hypertensive emergency and hypertensive urgency

1.9. Pathophysiology of Epilepsy

1.9.1. Pharmacokinetics of antiepileptic drugs
1.9.2. Pharmacological interactions of antiepileptic drugs
1.9.3. Combination treatment strategies
1.9.4. Use of antiepileptic drugs in special populations

1.10. Emerging and developing therapies for Migraine treatment

1.10.1. Therapies specifically targeting the pathophysiology of Migraine
1.10.2. Monoclonal therapies directed against calcitonin gene-related peptide (CGRP) in Migraine
1.10.3. PDE4 inhibitors as an emerging treatment for Migraine
1.10.4. Use of monoclonal antibodies in the prophylactic treatment of Migraine

Module 2. Pharmacology of the Central Nervous System

2.1. Ischemic Strokes

2.1.1. Advances in the early diagnosis of ischemic stroke
2.1.2. Evaluation and classification of the risk of ischemic stroke in asymptomatic patients
2.1.3. Thrombolytic treatment strategies in the acute phase of ischemic stroke
2.1.4. Biomarkers in Ischemic Stroke

2.2. Management of hypertension in acute ischemic stroke

2.2.1. Current guidelines and protocols for the management of hypertension in acute ischemic stroke
2.2.2. Pharmacologic treatment of hypertension in the acute phase of ischemic stroke
2.2.3. Blood pressure control strategies in ischemic stroke with thrombolytic therapy
2.2.4. Endovascular therapy and blood pressure control in acute ischemic stroke

2.3. Oropharyngeal angioedema due to Alteplase

2.3.1. Risk factors for the development of oropharyngeal angioedema after Alteplase administration
2.3.2. Clinical and differential diagnosis of oropharyngeal angioedema in patients treated with Aateplase
2.3.3. Management and treatment of acute oropharyngeal angioedema by Alteplase
2.3.4. Evaluation and follow-up of patients with a history of oropharyngeal angioedema prior to administration of Alteplase

2.4. Hemorrhagic stroke: intracerebral hemorrhage (ICH)

2.4.1. Diagnosis and classification of intracerebral hemorrhage in hemorrhagic stroke
2.4.2. Medical and pharmacological treatment of acute intracerebral hemorrhage
2.4.3. Neurosurgical and endovascular management of intracerebral hemorrhage
2.4.4. Multidisciplinary approach in the care of the patient with intracerebral hemorrhage

2.5. Cerebral edema

2.5.1. Cytotoxic versus vasogenic cerebral edema
2.5.2. Clinical evaluation and imaging of cerebral edema
2.5.3. Pharmacological strategies for the reduction of cerebral edema in specific pathologies
2.5.4. Effect of cerebral edema

2.6. Opioid overdose

2.6.1. Pharmacokinetics and pharmacodynamics of opioids involved in overdose
2.6.2. Role of the hospital pharmacist in opioid overdose prevention and education
2.6.3. Management of opioid withdrawal in the hospital setting
2.6.4. Naloxone and its use as an antidote in opioid overdose reversal

2.7. Opioid Withdrawal Syndrome

2.7.1. Epidemiology and risk factors for the development of Opioid Withdrawal Syndrome
2.7.2. Clinical evaluation and diagnosis of Opioid Withdrawal Syndrome in hospitalized patients
2.7.3. Pharmacological management of Opioid Withdrawal Syndrome in the hospital setting
2.7.4. Use of opioid agonist and antagonist drugs in the treatment of withdrawal syndrome

2.8. Agitated Patient Management

2.8.1. Epidemiology and risk factors associated with agitation in hospitalized patients
2.8.2. Pharmacotherapy for the management of acute agitation in inpatients
2.8.3. Use of antipsychotics and benzodiazepines in the treatment of agitation
2.8.4. Safety and prevention of complications in the management of the agitated patient

2.9. Pharmacology of Mucolytics and Expectorants in Respiratory Diseases

2.9.1. Pharmacological interactions between analgesics and substances of abuse
2.9.2. Pharmacological strategies for acute pain management in patients with opioid abuse
2.9.3. Acute pain Treatment in patient with Alcohol abuse
2.9.4. Assessment and management of addiction risk in patients with substance abuse requiring analgesia

2.10. Alcohol Withdrawal Syndrome

2.10.1. Clinical evaluation and diagnosis of Alcohol Withdrawal Syndrome in hospitalized patients
2.10.2. Pharmacotherapy for the management of Alcohol Withdrawal Syndrome in the hospital setting
2.10.3. Use of benzodiazepines and other drugs in the treatment of Alcohol Withdrawal Syndrome
2.10.4. Role of the hospital pharmacist in the management of Alcohol Withdrawal Syndrome

Module 3. Pharmacology of the surgical and polytraumatized patient

3.1. Triage

3.1.1. Triage in emergency and disaster situations:
3.1.2. Triage systems used in the hospital setting and their characteristics
3.1.3. Role of the pharmacist in the triage process and emergency care
3.1.4. Pharmaceutical triage protocols in different clinical scenarios

3.2. Resuscitation in the polytraumatized patient (PPT)

3.2.1. Hospital pharmacy in the PPT resuscitation team
3.2.2. Pharmacology of resuscitation: drugs and therapies used in PPT
3.2.3. Fluid therapy in the polytraumatized patient: types of solutions and considerations
3.2.4. Analgesia and sedation in the polytraumatized patient

3.3. Cranioencephalic Trauma (CET)

3.3.1. Classification and Severity of CET
3.3.2. Pain management and sedation in patients with CET
3.3.3. Treatment of Intracranial Hypertension
3.3.4. Use of neuroprotective agents in CET

3.4. Reversal of anticoagulants

3.4.1. Importance of anticoagulant reversal in specific clinical situations
3.4.2. Risk-benefit assessment in anticoagulant reversal
3.4.3. Reversal of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH)
3.4.4. Antidotes and reversal agents for direct oral anticoagulants (OACDs)

3.5. Acute Pain Management

3.5.1. Classification and scales for the evaluation of acute pain
3.5.2. Principles and guidelines of pharmacological management of acute pain
3.5.3. Multimodal Analgesia
3.5.4. Intravenous, oral and transdermal analgesia

3.6. Spinal shock

3.6.1. Evaluation and classification of spinal shock
3.6.2. Medications to stabilize blood pressure in spinal cord shock
3.6.3. Pain Management in Patients with Spinal shock
3.6.4. Neuroprotective agents in spinal shock

3.7. Hypovolemic Shock

3.7.1. Evaluation and classification of Hypovolemic Shock shock
3.7.2. Fluid therapy and volume replacement in hypovolemic shock
3.7.3. Types of solutions and electrolytes used in volume replacement
3.7.4. Use of vasoactive agents in the management of hypovolemic shock

3.8. Penetrating Trauma

3.8.1. Evaluation and classification of patients with penetrating trauma
3.8.2. Initial management and pharmacological stabilization of the trauma patient
3.8.3. Use of hemostatic agents and pharmacologic hemostasis
3.8.4. Antibiotherapy in penetrating trauma patients

3.9. Open Fractures

3.9.1. Initial evaluation and emergency management of patients with open fractures
3.9.2. Use of analgesia and sedation in patients with open fractures
3.9.3. Adjuvant therapies in the acceleration of bone healing
3.9.4. Use of analgesics and anti-inflammatory drugs in the management of pain in open fractures

3.10. Moderate sedation

3.10.1. Indications and contraindications of moderate sedation
3.10.2. Evaluation and selection of the appropriate level of sedation for each patient
3.10.3. Management of anxiety and pain in procedures with moderate sedation
3.10.4. Monitoring and patient safety during moderate sedation

Get an effective update on pain management and sedation in CTE patients with the highest quality multimedia content”